Conor MacKay
Stock Analyst at BMO Capital
(1.02)
# 3,916
Out of 4,696 analysts
6
Total ratings
20%
Success rate
-7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Conor MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintained: Buy | $192 | $126.63 | +51.62% | 3 | Aug 17, 2026 | |
| NAMS NewAmsterdam Pharma Company | Rated: Buy | $58 | $25.59 | +126.65% | 2 | Aug 5, 2026 | |
| TRVI Trevi Therapeutics | Initiated Coverage: Buy | $36 | $17.05 | +111.14% | 1 | Jul 21, 2026 |
Insmed
Aug 17, 2026
Maintained: Buy
Price Target: $192
Current: $126.63
Upside: +51.62%
NewAmsterdam Pharma Company
Aug 5, 2026
Rated: Buy
Price Target: $58
Current: $25.59
Upside: +126.65%
Trevi Therapeutics
Jul 21, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $17.05
Upside: +111.14%